Eupraxia Pharmaceuticals (EPRX) Cash from Financing Activities (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Cash from Financing Activities data on file, last reported at $68.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 15852.39% year-over-year to $68.6 million in Q1 2026; TTM through Mar 2026 was $144.2 million, a 525.81% increase from a year earlier, with the FY2025 full-year figure at $76.1 million, up 66.12% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $68.6 million, up from $1.5 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for EPRX reached as high as $73.9 million in Q3 2025 and fell as low as -$4.6 million in Q3 2024.
• Historically, Cash from Financing Activities has averaged $16.3 million across 4 years, with a median of $1.5 million in 2025.
• On a YoY basis, Cash from Financing Activities climbed as much as 532658.26% in 2024 and fell as far as 198.36% in 2024.
• Year by year, Cash from Financing Activities stood at $5956.0 in 2023, then surged by 532658.26% to $31.7 million in 2024, then slumped by 95.3% to $1.5 million in 2025, then soared by 4499.97% to $68.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $68.6 million in Q1 2026, $1.5 million in Q4 2025, and $73.9 million in Q3 2025.